
Hodgkin lymphoma Program in Pharmaceutical Benefits Scheme (PBS) 012-18042700

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS-subsidised brentuximab vedotin and
pembrolizumab for patients with relapsed or refractory Hodgkin lymphoma
and who have failed autologous stem cell transplant (ASCT) or are ASCT
naïve.

Hodgkin lymphoma and listing dates

Hodgkin lymphoma is a cancer of the immune system.

Listing dates are:

-   brentuximab vedotin- 1 April 2017
-   pembrolizumab - 1 May 2018

For more information, see Written Authority Required Drugs.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS schedule and the Services Australia
website.

Related links

Contacting a Health Service Delivery Division Programme Support Officer
(PSO)

Manage work items in PaNDA

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Process written authority approval requests

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
